<?xml version="1.0" encoding="UTF-8"?>
<p id="Par60">Ribavirin is a nucleotides derivative competing with physiological nucleotide for RdRp active site [
 <xref ref-type="bibr" rid="CR60">60</xref>, 
 <xref ref-type="bibr" rid="CR61">61</xref>]. Through the outbreak of SARS in Hong Kong, ribavirin was widely used for patients with or without the simultaneous use of steroids [
 <xref ref-type="bibr" rid="CR62">62</xref>]. The EC
 <sub>50</sub> against COVID-19 for Ribavirin determined at 109.5 μM [
 <xref ref-type="bibr" rid="CR63">63</xref>]. Based on previous studies about SARS and MERS, the combination of ribavirin and IFN-β, decreases the viral replication and disease severity in animal models [
 <xref ref-type="bibr" rid="CR64">64</xref>]. Due to unfavorable reactions, the proper dose of ribavirin in the clinical application should be given carefully.
</p>
